FierceBiotech Dec 11, 2025 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
FierceBiotech Dec 11, 2025 Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
FierceBiotech Dec 11, 2025 FDA clears Lumosity brain training games as a prescription app for adult ADHD
FierceBiotech Dec 11, 2025 Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech
FierceBiotech Dec 11, 2025 Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs
FierceBiotech Dec 10, 2025 Francis Medical gets FDA green light for water vapor ablation to treat prostate cancer
FierceBiotech Dec 10, 2025 Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal
FierceBiotech Dec 10, 2025 Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies
FierceBiotech Dec 10, 2025 Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans
FierceBiotech Dec 10, 2025 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
FierceBiotech Dec 10, 2025 Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025
FierceBiotech Dec 9, 2025 Teleflex inks $2B in divestment deals for OEM, urology and acute care units
FierceBiotech Dec 9, 2025 ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma